One of the current strategies to manage cancer overgrowth is inhibiting a trans-membrane glycoprotein called Epidermal growth factor receptor (EGFR) due to its essential role in intracellular signalling, morphogenesis, and differentiation.6–8. This evidence concerns the gene EGFR and cancer.